60 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
9
Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
Merck
25
Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors.
Glaxosmithkline
29
Structure-Activity Relationship of Azaindole-Based Glucokinase Activators.
Servier Research Institute of Medicinal Chemistry
24
Design and Synthesis of Acetylenyl Benzamide Derivatives as Novel Glucokinase Activators for the Treatment of T2DM.
Yuhan Research Institute
45
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket.
Amgen
26
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.
Amgen
20
Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Yuhan Research Institute
2
Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPAR¿.
Peking Union Medical College
24
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept.
Amgen
31
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles.
Amgen
6
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.
Pfizer
18
Identification of a new class of glucokinase activators through structure-based design.
Array Biopharma
29
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.
Pfizer
3
Small-Molecule Allosteric Activation of Human Glucokinase in the Absence of Glucose.
Florida State University
28
Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus.
Yuhan Research Institute
16
The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold.
AstraZeneca
19
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
Pfizer
13
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Pfizer
29
Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators.
Chinese Academy of Sciences
33
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.
Pfizer
23
Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.
AstraZeneca
21
Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.
Chinese Academy of Sciences
16
The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators.
Banyu Tsukuba Research Institute
30
Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators.
Banyu Tsukuba Research Institute
23
Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators.
Banyu Tsukuba Research Institute
30
Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy.
Banyu Tsukuba Research Institute
11
Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators.
Banyu Tsukuba Research Institute
25
Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.
Banyu Tsukuba Research Institute
33
Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators.
Banyu Tsukuba Research Institute
13
SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.
(Osi) Prosidion
17
Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
Advinus Therapeutics
6
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy.
AstraZeneca
23
Discovery, synthesis and biological evaluation of novel glucokinase activators.
AstraZeneca
26
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1
Bristol Myers Squibb
41
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
Beijing Normal University
45
Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.
Biogen
9
Design, synthesis, and pharmacological evaluation of 2-(4-sulfonylphenyl)-2-[(E)-pyrrolidin-1-ylimino]-N-thiazoleacetamides as glucokinase activators.
Chiba University
34
Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator.
Array Biopharma
7
Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times.
Istituto Italiano Di Tecnologia
27
Novel Series of Potent Glucokinase Activators Leading to the Discovery of AM-2394.
Amgen
25
5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties.
Amgen
30
Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors.
Zhejiang University
9
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
University of Florida
24
Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Binding: Strategic Use of a N → S (nN → σ*S-X) Interaction for Conformational Constraint.
Amgen
47
Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.
China Pharmaceutical University
26
Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators.
Takeda California
7
Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
Merck
43
6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
University of Pittsburgh
15
Substituted benzamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
Vanderbilt University